$PIQ
Patent granted in Canada protecting the intellectual property for PromarkerEso proprietary blood test for the early diagnosis of esophageal adenocarcinoma (EAC)
The patent underpins the commercialisation pathway in North America, enabling direct sales,
future partnerships and licensing opportunities
Patents for the PromarkerEso diagnostic test now cover multiple jurisdictions including Australia,Canada, China, Hong Kong, Europe and the USA